Analysis of Metabolic Patterns of Recurrence on PET-CT for Locally Advanced Head and Neck Cancer (LAHNC) Patients Treated Definitively by IMRT-The Impact of PET-CT for Treatment Planning and Surveillance: Preliminary Results

2011 ◽  
Vol 81 (2) ◽  
pp. S549-S550
Author(s):  
R.S. de Andrade ◽  
G. Kubicek ◽  
A.S. Nelson ◽  
D. Nelson ◽  
D.E. Heron
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Treatment Planning ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Preliminary Results ◽  
Pet Ct ◽  
The Impact ◽  
Patterns Of Recurrence

Integrated PET-CT treatment planning of locally advanced head and neck cancer: a review of imaging features and the contribution to clinical outcomes

2021 ◽  
pp. 1-3
Author(s):  
Federico Ampil ◽  
Michelle Norton
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Treatment Planning ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Tumour Response ◽  
Tumour Volume ◽  
Imaging Features ◽  
Advanced Head ◽  
Pet Ct

Abstract Aim: Little is known about how integrated positron emission tomography-computed tomography (IPET-CT), both imaging tools and not methods of treatment, contributes to head and neck cancer patients’ outcomes. We analysed the clinical PET-CT findings and their correlation to the effects of applied contemporary disease management. Methodology: A retrospective analysis of 29 individuals who underwent treatment planning fusion of PET-CT for radiochemotherapy of locally advanced head and neck cancer between 2010 and 2016 was undertaken. Gross tumour volumes were categorised as small (≤36 cm3) or large (>36 cm3), and tumour responses to therapy were classified as complete or incomplete. Results: The overall rates of complete tumour response (CTR), 3-year crude survival and failure (all types included) were 80%, 41% and 55%, respectively. Comparative analysis of tumour volume subsets revealed no significant differences in the rates of CTR (p > 0.80), 3-year survival (p > 0.30) and locoregional recurrence (p > 0.70). CTR was associated with improved prognosis (p > 0.05) and fewer tumour relapses (p < 0.02). Conclusion: Our findings, although not truly conclusive, appear in line with those in the literature. Smaller tumour volumes and CTRs shown on integrated PET-CT are likely to play important roles in the promotion of better prognosis, but further study with larger patient numbers and more data are needed.

Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer

2014 ◽  
Vol 17 (2) ◽  
pp. 139-144 ◽  
Author(s):  
F. Arias ◽  
V. Chicata ◽  
M. J. García-Velloso ◽  
G. Asín ◽  
M. Uzcanga ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Fdg Pet ◽  
Locally Advanced ◽  
Management Plan ◽  
Advanced Head ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Correction to: Planning comparison of five automated treatment planning solutions for locally advanced head and neck cancer

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
J. Krayenbuehl ◽  
M. Zamburlini ◽  
S. Ghandour ◽  
M. Pachoud ◽  
S. Tanadini-Lang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Treatment Planning ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head

Beyond race: The impact of ethnicity on the treatment outcome of locally advanced head and neck cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16500-16500
Author(s):  
C. J. Calfa ◽  
M. Escalon ◽  
S. Zafar ◽  
E. Lopez ◽  
V. Patel ◽  
...  
Keyword(s):  
Overall Survival ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Statistical Significance ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Advanced Head ◽  
Kaplan Meier ◽  
The Impact

16500 Background: Self identified racial groups share an unequal burden of head and neck cancer . Recent evidence suggests that outcome among races is different and the causes are multifactorial. Nonetheless, differences among ethnic groups have not been reported. Herein, we decided to analyze differences in treatment response and outcome among our white and Hispanic patient population treated for locally advanced head and neck cancer. Methods: Patients were identified using the tumor registry. We reviewed retrospectively the data from medical records. 100 white Hispanics (WH) and 50 white non-Hispanics (WNH) diagnosed with locally advanced head and neck cancer and treated at our institution from 2004 to 2005, were eligible for the study. Standard statistical analysis, including Kaplan-Meier survival curve and Cox proportional hazard models were used. P value of <0.05 was considered for statistical significance. Results: Preliminary results reveal that, in our study population, median age at diagnosis, gender, performance status (ECOG 0–2) and squamous cell histology did not differ significantly between the two groups. Stage 4 at diagnosis was more commonly observed in Hispanics as opposed to WNH (85.7% vs 68.6%) (P = 0.1). Surgery was more commonly used as an initial treatment option in Hispanics than WNH (42.8% vs 28.6%) (P = 0.18) while chemotherapy was less likely to be used (78.6% vs. 91.4%) (P = 0.15). Hispanics were more likely to smoke than WNH (P = 0.0003) and were equally exposed to chronic alcohol use. Patients from the Hispanic group were more likely to respond to therapy than whites by Chi-squared analysis but this difference was not statistically significant (P = 0.09). No differences were seen in disease free survival. Kaplan-Meier estimate of median overall survival was 16 months for Hispanics vs. 25 months for whites but this difference did not reach statistical significance (P = 0.26). Final analysis will be available at the time of the annual meeting. Conclusion: In our experience, a trend for decrease overall survival was noted in the Hispanic ethnic group. This may be in part due to more advanced stage at presentation. Nonetheless, in order to definitively answer this question, further research is warranted. No significant financial relationships to disclose.

Impact of cetuximab on chemoradiation use in older patients with locally advanced head and neck cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6594-6594 ◽  
Author(s):  
Shrujal S. Baxi ◽  
Eric Jeffrey Sherman ◽  
Coral L Atoria ◽  
Nancy Y. Lee ◽  
David G. Pfister ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Side Effect ◽  
Locally Advanced ◽  
Definitive Treatment ◽  
Side Effect Profile ◽  
Advanced Head ◽  
The Impact ◽  
Over Time

6594 Background: The benefit of chemoradiation (CTRT) in the treatment of locally advanced head and neck cancer (LAHNC) declines in older and sicker patients. In 2006, the FDA approved cetuximab in LAHNC. Cetuximab with radiation has a perceived lower side effect profile compared to standard chemotherapies used in CTRT. Our objective was to examine the impact of cetuximab on the use of CTRT in elderly patients with LAHNC. Methods: We identified adults aged 66 and older diagnosed with LAHNC between 1999 and 2007 in the Surveillance Epidemiology and End Results (SEER)-Medicare linked database. Treatment was categorized as CTRT or other based on Medicare claims within 6 months of diagnosis. We excluded patients who did not receive definitive treatment. In patients who had CTRT, we identified use of cetuximab based on drug-specific billing codes. We assessed trends in the use of CTRT over the entire study period and in the use of cetuximab since 2006. We examined the influence of age and comorbidity on the likelihood of receiving CTRT before and after 2006 adjusting for clinical and demographic factors. Results: We identified 4,809 patients with LAHNC. One-fourth were ≥80 years and almost a fifth had a Charlson comorbidity score (CCS) of ≥2. Overall more than 20% of patients received CTRT. The use of CTRT more than tripled over time, from 10% of patients diagnosed in 1999 to 38% in 2007 (p<0.0001 for trend). Of the 336 patients who had CTRT since 2006, 45% received cetuximab. Prior to 2006, patients ≥80 years or those with a CCS of ≥2 were significantly less likely to be treated with CTRT compared to younger patients or those with a CCS of 0. In patients diagnosed in 2006 or later, age and comorbidity no longer predicted the likelihood of receiving CTRT. Conclusions: In this population-based cohort of older adults, the use of CTRT increased substantially over time. The availability of cetuximab, with a perceived gentler side effect profile, may have increased the use of CTRT, especially in older and sicker patients. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document